Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006256 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00006256 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 44 participants.
The verdict
NCT00006256, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining paclitaxel with radiation therapy may kill more tumor cells. PURPOSE: This trial is to study the effectiveness of concurrent administration of chemotherapy and radiation therapy in treating women who have stage II or stage III breast cancer by examining the complications and cosmetic effects.
Interventions
- DRUG paclitaxel
- RADIATION radiation therapy
- PROCEDURE adjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2000-06-08 |
| Est. Completion | 2023-11-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006256
The ClinicalTrials.gov registry entry for NCT00006256 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which paclitaxel is the first listed.
NCT00006256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006256 about?
NCT00006256 is a clinical study titled "Paclitaxel Plus Radiation Therapy in Treating Women With Stage II or Stage III Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining paclitaxel with radiation therapy may kill more tumor cells. PURPOSE: This trial is to study the effecti...
What is the current status of trial NCT00006256?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2000-06-08. Estimated completion is 2023-11-20.
What interventions are being tested in trial NCT00006256?
The interventions under investigation include: paclitaxel (DRUG), radiation therapy (RADIATION), adjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00006256?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.